Photocure Investor Hub
Investment highlights
A commercial-stage company focused on bladder cancer
Hexvix®/Cysview® is a product for the detection of bladder cancer:
- Established position as an innovation leader in the large and underserved bladder cancer treatment market.
- Treatment guidelines and reimbursement supports market penetration.
- In excess of USD 40M in global market sales.
- Specialist salesforce established in the U.S. and Europe with additional potential value in other territories through our partners; Asieris MediTech Co., Ltd. (China), Endotherapeutics Group (Australia/New Zealand), Genotests (Chile) and IGL Medical (Israel).
Value-building opportunity
- Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
- Opportunities following the FDA approval of Cysview® for use with flexible cystoscope.
- Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.
Investor news
Latest reports
Event highlights
Congresses
Society of Urologic Oncology 2023 Annual Meeting (SUO)
28 Nov 2023 - 1 Dec 2023https://suonet.org/meetings/upcoming-meetings.aspxConferences
Nordic- American Healthcare Conference in New York
6 Dec 2023 - 7 Dec 2023Conferences
SEB Healthcare Seminar 2023 in Stockholm
21 Nov 2023 - 23 Nov 2023Analyst coverage Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management. Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
ABG Sundal Collier
DNB Markets
Patrik Ling
Tel: +46 733 26 37 69
Handelsbanken
Rickard Anderkrans
Tel: +46 8 701 1995
Norne Securities AS
Tomas Skeivys
Tel: +47 21 95 37 49